TransCode Therapeutics Overview
Latest ROE for TransCode Therapeutics: 226.14% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow226.14%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for RNAZ is 226.14%. That is above the Healthcare sector average of 21.67%. Investors often review this figure alongside TransCode Therapeutics's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, RNAZ currently prints 226.14% for ROE, while the sector average sits near 21.67%. That is roughly 943.7% above the sector mean. Large gaps often invite a closer look at TransCode Therapeutics's growth, margins, and balance sheet.
Return on Equity shows how effectively TransCode Therapeutics converts resources into returns. At 226.14%, RNAZ may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting RNAZ's ROE (226.14%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack TransCode Therapeutics's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
